Shingrix (herpes zoster vaccine (recombinant, adjuvanted))
- Region
- 🇪🇺 EU
- Active substance
- herpes zoster vaccine (recombinant, adjuvanted)
- Company
- GlaxoSmithKline Biologicals S.A.
- Status
- Authorised
- Therapeutic area
- Herpes Zoster
- EU approval
- Wed 21 Mar 2018
- Application
- EMEA/H/C/004336
- ATC
- J07BK03
- Official record
- www.ema.europa.eu
Indication
Shingrix is indicated for prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN), in: adults 50 years of age or older; adults 18 years of age or older at increased risk of HZ. The use of Shingrix should be in accordance with official recommendations.
Regulatory milestones
No milestones recorded in the last year.
Follow Shingrix
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.